
The FDA has approved Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients …
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

